The Cystic Fibrosis Core Center at Case Western Reserve University has three main areas of focus- epithelial cell biology, inflammation and host defense in the lung, and clinical studies in cystic fibrosis (CF). The epithelial cell biology effort is mainly in the areas of ion transport, intracellular signalling, and epithelial cell differentiation . The lung inflammation and host defenses effort focuses on mucosal immunity and the impact of persistent neutrophilic infiltration on the function of the host's defenses. Clinical studies include investigations on the pathophysiology of the CF lung disease, as well as three clinical trials now in progress and another in the pilot stages. The Center is devoted to discovering the underlying defect in CF, elucidating the nature of the pulmonary disease which takes the patients' lives, and in translating advances at the lab bench to the bedside as rapidly as is safe. The work is supported by an Administrative Component and six other Core facilities: the Patient Core, Cell Physiology Core, Epithelial Cell Culture Core, Inflammatory Mediator Core, Morphology Core, and Bronchoalveolar Lavage/Immunology Core. In addition, a pilot and feasibility program is proposed for continuation with three projects: one project by Dr. Michael Infeld on the determinants of mucous differentiation of epithelial cells is proposed for continuation; Dr. Michael Konstan proposes a one-year project designed to establish the feasibility of a clinical trial of antiproteases in CF; and Dr. Thomas Gerken proposes to obtain a mucus-secreting intestinal epithelial cell line which he can label with 13 C precursors in order to examine, by nuclear magnetic resonance, the intramolecular interactions in mucins both in the secretory granules and as they are released.

Agency
National Institute of Health (NIH)
Institute
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Type
Center Core Grants (P30)
Project #
5P30DK027651-13
Application #
2138035
Study Section
Diabetes, Endocrinology and Metabolic Diseases B Subcommittee (DDK)
Project Start
1983-01-01
Project End
1996-03-31
Budget Start
1995-05-01
Budget End
1996-03-31
Support Year
13
Fiscal Year
1995
Total Cost
Indirect Cost
Name
Case Western Reserve University
Department
Pediatrics
Type
Schools of Medicine
DUNS #
077758407
City
Cleveland
State
OH
Country
United States
Zip Code
44106
Lai, Nicola; M Kummitha, China; Rosca, Mariana G et al. (2018) Isolation of mitochondrial subpopulations from skeletal muscle: Optimizing recovery and preserving integrity. Acta Physiol (Oxf) :e13182
Donnola, Shannon B; Dasenbrook, Elliott C; Weaver, David et al. (2017) Preliminary comparison of normalized T1 and non-contrast perfusion MRI assessments of regional lung disease in cystic fibrosis patients. J Cyst Fibros 16:283-290
VanDevanter, D R; Flume, P A; Morris, N et al. (2016) Probability of IV antibiotic retreatment within thirty days is associated with duration and location of IV antibiotic treatment for pulmonary exacerbation in cystic fibrosis. J Cyst Fibros 15:783-790
Jiang, Kai; Jiao, Sen; Vitko, Megan et al. (2016) The impact of Cystic Fibrosis Transmembrane Regulator Disruption on cardiac function and stress response. J Cyst Fibros 15:34-42
Bruscia, Emanuela M; Bonfield, Tracey L (2016) Cystic Fibrosis Lung Immunity: The Role of the Macrophage. J Innate Immun 8:550-563
Hsu, Daniel; Taylor, Patricia; Fletcher, Dave et al. (2016) Interleukin-17 Pathophysiology and Therapeutic Intervention in Cystic Fibrosis Lung Infection and Inflammation. Infect Immun 84:2410-21
Rymut, Sharon M; Kampman, Claire M; Corey, Deborah A et al. (2016) Ibuprofen regulation of microtubule dynamics in cystic fibrosis epithelial cells. Am J Physiol Lung Cell Mol Physiol 311:L317-27
Than, B L N; Linnekamp, J F; Starr, T K et al. (2016) CFTR is a tumor suppressor gene in murine and human intestinal cancer. Oncogene 35:4179-87
Darrah, Rebecca; Nelson, Rebecca; Damato, Elizabeth G et al. (2016) Growth Deficiency in Cystic Fibrosis Is Observable at Birth and Predictive of Early Pulmonary Function. Biol Res Nurs 18:498-504
VanDevanter, Donald R; Morris, Nathan J; Konstan, Michael W (2016) IV-treated pulmonary exacerbations in the prior year: An important independent risk factor for future pulmonary exacerbation in cystic fibrosis. J Cyst Fibros 15:372-9

Showing the most recent 10 out of 445 publications